Skip to main content
Premium Trial:

Request an Annual Quote

Sygnis Pharma Buys TGen Spin-out Amnestix for $6.3M

NEW YORK (GenomeWeb News) – German drug developer Sygnis Pharma has bought Amnestix, a spin-out from the Translational Genomics Research Institute, for €4 million ($6.3 million) in a cash and shares deal, Sygnis said today.
 
Amnestix, which was started by TGen researchers Dietrich Stephan and Matthew Huentelman in 2006 and was funded by the Brain Trust Accelerator Fund, is focused on developing therapeutics that can improve cognition and memory functions that are damaged by neurological diseases.
 
Amnestix has discovered a series of genes and pathways involved in memory performance through whole-genome association analysis. The company has also found novel uses for protein kinase inhibitors that it believes could be used to treat conditions such as cognitive impairment and dementia.
 
Sygnis plans to continue to develop these compounds for use in treating age-related memory problems, Alzheimer’s disease, and other neurological diseases. Sygnis also said that the deal gives it access to some TGen projects that are focused on central nervous system disorders.
 
Amnestix CEO Karoly Nikolich will remain with the company and will help Sygnis expand its partnering, scientific, and financial networking.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.